Medexus Pharmaceuticals (TSE:MDP) Sets New 1-Year High - What's Next?

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$3.83 and last traded at C$3.84, with a volume of 84289 shares. The stock had previously closed at C$3.60.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MDP shares. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective on the stock in a research report on Wednesday. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Finally, Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research note on Monday, September 30th. Two equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy" and a consensus target price of C$5.25.

Medexus Pharmaceuticals Stock Up 13.1 %

The stock has a market cap of C$99.84 million, a P/E ratio of 81.40 and a beta of 1.96. The company has a 50-day simple moving average of C$2.74 and a two-hundred day simple moving average of C$2.52.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.